Further, the worldwide population with the condition is estimated to be 22,000 (6,000 in the US). At todays close RETA M/C was $1.14b, (which rose to almost $3.5b at the height of after hours trading). Together with the 370k price tag these are similarities with Neuren. (I realise we only get royalties, but we don't have all the expenses associated with ownership of the drug).
Also of interest is this comment from an RBC Capital Markets analyst (which supports the Steve Davis view that the FDA's Billy Dunn resignation will not impact our decision).
"Overall, we believe loss of a more permissive, industry-friendly voice is a long-term negative, though near-term there should be some degree of continuity which limits the effects".
Ann: Rett Syndrome NDA accepted for Priority Review by FDA, page-155
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.27 |
Change
0.920(6.41%) |
Mkt cap ! $1.951B | |||
| Open | High | Low | Value | Volume |
| $14.35 | $15.27 | $14.35 | $8.720M | 579.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $15.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.27 | 3638 | 4 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |